Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer
Sponsor: Vaccinogen Inc
Summary
OncoVAX® is the first cancer therapy that both prevents cancer recurrence and addresses the diversity of cancer cells. In this pivotal randomized, multicenter Phase IIIb study in patients with Stage II colon cancer, OncoVAX is designed to use a patient's own cancer cells to mobilize the body's immune system to prevent the return of colon cancer following surgery.
Official title: A Randomized Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
550
Start Date
2026-08
Completion Date
2033-08
Last Updated
2026-02-02
Healthy Volunteers
No
Conditions
Interventions
OncoVAX and Surgery
OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following standard-of-care surgical tumor resection for Stage II colon cancer
Surgery
Surgical resection of Stage II colon cancer
Locations (1)
Halifax Health Medical Center
Port Orange, Florida, United States